Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adverse Event Initiatives Aim For Better Data, Easier Reporting

This article was originally published in The Silver Sheet

Executive Summary

DEVICE ADVERSE EVENT REPORTING is gradually becoming less burdensome and more standardized as the result of initiatives at FDA and internationally. The MedSun program for a small subset of hospitals is well on its way toward eventually replacing universal user reporting of adverse events, with FDA officials saying the system is providing high quality information that can help manufacturers better understand problems that health care practitioners encounter with their products. Meanwhile, the Global Harmonization Task Force anticipates greater ease for industry in reporting adverse events to international regulatory bodies under its comprehensive reporting guidance, now nearly complete. National regulatory authorities, in turn, will find their job of sharing event data with one another simpler under a new coding system developed by ISO Technical Committee 210

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel